Single nucleotide instability without microsatellite instability in rat mammary carcinomas.
Mutation frequencies (MnFs) of the lacI transgene and mutation rates (MRs) of the endogenous hprt gene were analyzed in two mammary carcinoma cell lines that we established from mammary carcinomas that had been induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in female lacI-transgenic rats. Using the lacI transgene, corrected MnF, which is the number of independent lacI mutations that occurred while 102 cells expanded into 10(7) cells and which reflect the dynamic increase of point mutations, was measured. The corrected MnFs in the two mammary carcinoma cell lines (59 x 10(-6) and 72 x 10(-6) mutations) were significantly higher than that in the primary culture of normal mammary epithelium (4.7 x 10(-6)). MRs of the hprt gene in the two mammary carcinoma cell lines (8.2 x 10(-7) and 11 x 10(-7) mutations/hprt/cell division) were also higher than the same control (1.4 x 10(-7)). A:T to C:G transversion was observed at significantly higher frequencies in the two cell lines (6 of 24 and 6 of 25 for lacI; 10 of 67 and 19 of 92 for hprt) than in the control (0 of 6 for lacI; 0 of 4 for hprt). Taking advantage of the lacI transgene, high frequencies of A:T to C:G transversion (6 of 38 and 8 of 33, respectively) was also confirmed in the primary carcinomas of the two cell lines, which indicated the presence of a common abnormality in the cell lines and in the primary carcinomas. Both the established cell lines and their primary carcinomas were negative for microsatellite instability, which is known to be caused mainly by mismatch repair insufficiency and to increase point mutations, and for p53 mutations. These findings showed that the two cell lines, and possibly their primary carcinomas, had increases in the MRs of point mutations attributable to a mechanism(s) different from mismatch repair insufficiency, and we would suggest that such a state be designated as single nucleotide instability (SNI).
Watanabe
N
N
Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan.
Okochi
E
E
Hirayama
Y
Y
Shimada
Y
Y
Yanagihara
K
K
Yoshida
M C
MC
Takahashi
S
S
Mochizuki
M
M
Sugimura
T
T
Nagao
M
M
Ushijima
T
T
D000818:Animals; D001426:Bacterial Proteins / Q000235:genetics*; D001483:Base Sequence; D002273:Carcinogens / Q000633:toxicity; D004252:DNA Mutational Analysis; D029968:Escherichia coli Proteins; D005260:Female; D016158:Genes, p53 / Q000235:genetics; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics*; D007093:Imidazoles / Q000633:toxicity; D056968:Lac Repressors; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000235:genetics*; D018895:Microsatellite Repeats / Q000235:genetics*; D008969:Molecular Sequence Data; D009154:Mutation; D016133:Polymerase Chain Reaction; D020641:Polymorphism, Single Nucleotide; D018807:Polymorphism, Single-Stranded Conformational; D051381:Rats; D017207:Rats, Sprague-Dawley; D012097:Repressor Proteins / Q000235:genetics*; D019076:Transgenes; D014407:Tumor Cells, Cultured
D001426:Bacterial Proteins; D002273:Carcinogens; D029968:Escherichia coli Proteins; D007093:Imidazoles; D056968:Lac Repressors; D012097:Repressor Proteins; C049584:2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; D007041:Hypoxanthine Phosphoribosyltransferase